Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795931 | 1.00 | IDO1 (0.45) | IDO1ALDH1A1HTTXBP1RAB9A | |
| SCHEMBL3318970 | 1.00 | IDO1 (0.45) | IDO1ALDH1A1HTTXBP1RAB9A | |
| SCHEMBL8445624 | 0.89 | IDO1 (0.42) | IDO1 | |
| SCHEMBL3973439 | 0.89 | IDO1 (0.42) | IDO1 | |
| SCHEMBL1148693 | 0.89 | IDO1 (0.42) | IDO1 | |
| SCHEMBL30523117 | 0.89 | IDO1 (0.42) | IDO1 | |
| SCHEMBL1148775 | 0.89 | IDO1 (0.42) | IDO1 | |
| Water SCHEMBL27660893 | 0.88 | IDO1 (0.41) | IDO1 | |
| SCHEMBL4794631 | 0.83 | IDO1 (0.45) | IDO1ALDH1A1HTTXBP1BLM | |
| SCHEMBL3541769 | 0.83 | IDO1 (0.45) | IDO1ALDH1A1HTTXBP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021112933-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| WO-2003095419-A1 | TETRALIN ISOCYANATES | BAYER MATERIALSCIENCE LLC (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003095419-A1 | TETRALIN ISOCYANATES | BAYER MATERIALSCIENCE LLC (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030212160-A1 | Tetralin isocyanates | COVESTRO LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030212160-A1 | Tetralin isocyanates | COVESTRO LLC | 2003-11-13 | — | — | US | disclosed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-4332724-A | OXIDATION IN PRESENCE OF COBALT CATALYST | AMERICAN CYANAMID CO. (US) | 1982-06-01 | — | — | US | disclosed |
| US-4062856-A | ANIMAL GROWTH REGULATOR, HERBICIDE | AMERICAN CYANAMID CO. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4005140-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3953506-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3953606-A | ANIMAL GROWTH STIMULATORS | AMERICAN CYANAMID COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | IDO1 4740/4885ALDH1A1 4150/4885HTT 868/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | IDO1 1137/4885ALDH1A1 1331/4885HTT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.